Articles on

Before we inform you how busy this week will be, it's worth mentioning the positive technical developments in cryptos, says Adam Button of
Supply tightness is everywhere you look. We have asphalt shortages in Texas, we have tightness of grain supply, aluminum shortages in China, copper tightness as well, says Phil Flynn of the PRICE Futures Group.
US benchmarks surged to new record highs Friday, states Bill Baruch of Blue Line Futures.
The week ahead will be dominated by earnings with Amazon, Apple, Facebook, Google, and Microsoft among the 165 S&P 500 (SPX) firms reporting, explains Ian Murphy of
Jacobs Engineering (J) carries our highest investment recommendation of 5-STARS, or Strong Buy, notes analyst Elizabeth Vermillion in CFRA Research's flagship newsletter, The Outlook.
Vanguard International Growth Fund Investor Shares (VWIGX) is a diversified, multi-manager mutual fund, explains Brian Kelly, mutual fund specialist and editor of MoneyLetter.
Here in the U.S., crude oil stockpiles are low and getting lower, falling six weeks in a row. Recently, we had the biggest four-week draw-down on oil stocks that America has seen in the last 40 years, asserts Sean Brodrick, editor of Wealth Megatrends.
Medicine has come a long way in the last few decades, and that pace shows little sign of slowing, explains Jim Woods, an exchange-trade fund specialist and the editor of The Deep Woods.
The European Central Bank’s monetary policy announcement was the most important event this week, but it did not inspire any breakout moves for EUR/USD, says Kathy Lien of   
Twice this month already, S&P 500 (SPX) has had a sharp one-day decline amidst deteriorating internal factors in the market, yet the Index quickly reversed back upward the very next day asserts Larry McMillan of Option Strategist.

Virtual Learning

With the recent acquisition of GWPH by Jazz Pharmaceuticals, many investors are wondering who might follow in their footsteps. Skye Bioscience (SKYE) has the right set-up—and advantages—to not just follow GW's leadership but carve a new path. SKYE is working to solve the world's leading cause of irreversible blindness by applying advanced science to uniquely unlock the therapeutic potential of cannabinoids and create important new pharmaceutical medicines. The lead program targets glaucoma, a disease with no cure and the world's leading cause of irreversible blindness. Preclinical data has demonstrated that SKYE's lead molecule, THCVHS, provides superior lowering of intraocular pressure, a key cause of vision loss, compared to the top commercially marketed classes of drugs that represent 80% of a nearly $7 billion market opportunity. With key value driving milestone and catalyst on the horizon SKYE is poised for significant growth.
From the retail investor appetite for micro-options contracts to the benefits of utilizing index options, explore strategies to incorporate new investment vehicles into your portfolio.

The best options trading strategy identifies stock moves before they happen so you can get in ahead of the herd, applies the right options combination to maximize probability with the potential for 100%+ ROI every time, and works consistently in both normal and volatile market conditions.

In his presentation Matt Choi, CMT, will show you how to find and place options trades to double your investment every time with this one strategy. After this 45-minute class, you'll have all the step-by-step instructions to start trading his strategy right away. This is a must-have for serious options traders.

Tom Smith will provide an overview of WRAP Technologies and how it is helping improve policing and law enforcement globally by providing tools that reduce the use of force to apprehend subjects. He will discuss WRAP's current technologies, the BolaWrap remote restraint device and WRAP Reality simulation-based training platform, as well as the growing market interest both in the US and internationally, new and extended BolaWrap pilot programs, and successful police field uses preventing escalation of force. He will also talk about WRAP's strong first-quarter 2021 financial results and operating metrics.
Against the backdrop of heightened tensions in US-China relations, strong economic data, and raw-material shortages and supply-chain issues, what can investors expect for the rest of the year? Our distinguished panel will dissect the economic, global trade, and political landscape and offer a unique perspective on the long- and short-term implications of these factors and more on your portfolio.
A major driver of cancer is defects in the switches that turn the biochemical pathways in cells on and off. Most cancer research over the past 30 years has focused on the on switches because the off switches, especially the master off switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients. Lixte has achieved a breakthrough with its novel, first-in-class lead compound, PP2A inhibitor LB-100, by demonstrating that it is readily tolerated in cancer patients at doses associated with anti-cancer activity. This innovative approach encourages cancer cells, weakened by chemo or other cancer therapies, to continue to replicate, leading to the more efficient death and elimination of those cells from the body.
Emerald Health Therapeutics is committed to creating new consumer and patient experiences with specialty recreational, medical, and wellness-oriented cannabinoid products. The company is focused on science-based innovation and product excellence, leveraging competencies in scientific know-how and research and development. Emerald is serving consumers and patients in Canada and establishing partnerships that extend its product lines and international reach.